Editor, – Two issues arise from Vol 22, No. 5. The article by John Tiller 'The new antidepressants - clinical applications' (Aust Prescr 1999;22:108-11) omits reference to sertraline as an agent approved for treatment of panic disorder. Panic disorder has been an approved indication for sertraline since December 1997.
In the article by Eve Hurley 'Assessing the statins' (Aust Prescr 1999;22:114-7) the self-test question 8, about primary prevention, correctly answered as 'true', could amount to less than the 'whole truth'. I suggest it would be more accurate to say that, based on studies reported to date, there is more evidence of benefit from statins in secondary prevention than there is in primary prevention (i.e. three trials versus one published to date). The statement offered is too absolute, and might get a pharmaceutical company into trouble with the Code of Conduct Committee if offered for promotional purposes.
M.M. Lawrie
Director, Medical Affairs
Pfizer Australia
West Ryde, N.S.W.